These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 27575715)
21. Animal models of CNS disorders. McGonigle P Biochem Pharmacol; 2014 Jan; 87(1):140-9. PubMed ID: 23811310 [TBL] [Abstract][Full Text] [Related]
22. True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence. Goetghebeur PJ; Swartz JE J Psychopharmacol; 2016 Jul; 30(7):586-94. PubMed ID: 27147593 [TBL] [Abstract][Full Text] [Related]
23. Failed drug discovery in psychiatry: time for human genome-guided solutions. Papassotiropoulos A; de Quervain DJ Trends Cogn Sci; 2015 Apr; 19(4):183-7. PubMed ID: 25727774 [TBL] [Abstract][Full Text] [Related]
24. Nanotechnological advances for the delivery of CNS therapeutics. Wong HL; Wu XY; Bendayan R Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125 [TBL] [Abstract][Full Text] [Related]
25. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Gribkoff VK; Kaczmarek LK Neuropharmacology; 2017 Jul; 120():11-19. PubMed ID: 26979921 [TBL] [Abstract][Full Text] [Related]
26. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. Cole PE; Schwarz AJ; Schmidt ME Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072 [TBL] [Abstract][Full Text] [Related]
27. Differential receptor-mediated drug targeting to the diseased brain. Rip J; Schenk GJ; de Boer AG Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042 [TBL] [Abstract][Full Text] [Related]
28. Targeting neuronal function for CNS drug discovery. Hempel CM; Werley CA; Dempsey GT; Gerber DJ Drug Discov Today Technol; 2017 Mar; 23():17-25. PubMed ID: 28647082 [TBL] [Abstract][Full Text] [Related]
29. Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic. Vuillemenot BR; Korte S; Wright TL; Adams EL; Boyd RB; Butt MT Toxicol Sci; 2016 Jul; 152(1):3-9. PubMed ID: 27354708 [TBL] [Abstract][Full Text] [Related]
30. The potential of antisense as a CNS therapeutic. Godfray J; Estibeiro P Expert Opin Ther Targets; 2003 Jun; 7(3):363-76. PubMed ID: 12783572 [TBL] [Abstract][Full Text] [Related]
32. [Functional role for GABA transporters in the CNS]. Hiramatsu M Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):187-92. PubMed ID: 24717607 [No Abstract] [Full Text] [Related]
33. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722 [TBL] [Abstract][Full Text] [Related]
34. Translational research in central nervous system drug discovery. Hurko O; Ryan JL NeuroRx; 2005 Oct; 2(4):671-82. PubMed ID: 16489374 [TBL] [Abstract][Full Text] [Related]
38. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. Yokley BH; Hartman M; Slusher BS ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461 [TBL] [Abstract][Full Text] [Related]
39. Prospects for the development of epigenetic drugs for CNS conditions. Szyf M Nat Rev Drug Discov; 2015 Jul; 14(7):461-74. PubMed ID: 26000723 [TBL] [Abstract][Full Text] [Related]